ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Medrad, a subsidiary of Bayer HealthCare, has signed an agreement to acquire Possis Medical for about $361 million.
With 2006 sales of $478 million, Medrad is a leading provider of contrast injection systems used to diagnose cardiovascular and other diseases. Possis, based near Minneapolis, posted $67 million in revenues in its latest fiscal year. It markets mechanical thrombectomy devices used to treat narrowed or blocked arteries and veins.
The companies say the new business will be a leader in the cardiovascular intervention field, with a focus on high-pressure intravascular fluid management. "This merger will capitalize on both companies' strengths to deliver growth in our current markets and create a formidable cardiovascular portfolio in the future," says Medrad CEO John P. Friel.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter